Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001072613-17-000002
Filing Date
2017-01-04
Accepted
2017-01-04 13:45:36
Documents
1
Group Members
ARCH VENTURE PARTNERS VI, L.P.ARCH VENTURE PARTNERS VI, LLCCLINTON BYBEEKEITH CRANDELLROBERT NELSEN

Document Format Files

Seq Description Document Type Size
1 ARCH VENTURE FUND VI, L.P. - SCHEDULE 13DA - AMEND. #1 (BELLEROPHON THERAPEUTICS arch-beller13da1_18015.htm SC 13D/A 49243
  Complete submission text file 0001072613-17-000002.txt   50939
Mailing Address 8755 W HIGGINS RD STE 1025 CHICAGO IL 60631
Business Address 8755 W HIGGINS RD STE 1025 CHICAGO IL 60631 7733806600
ARCH VENTURE FUND VI LP (Filed by) CIK: 0001222135 (see all company filings)

EIN.: 000000000
Type: SC 13D/A

Mailing Address 184 LIBERTY CORNER ROAD, SUITE 302 WARREN NJ 07059
Business Address 184 LIBERTY CORNER ROAD, SUITE 302 WARREN NJ 07059 908-574-4770
Bellerophon Therapeutics, Inc. (Subject) CIK: 0001600132 (see all company filings)

EIN.: 473116175 | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-88741 | Film No.: 17504582
SIC: 2834 Pharmaceutical Preparations